Richard Shippy (@RichShippy) header
Richard Shippy (@RichShippy) profile picture

Biotech exec advancing genomics and multiomics. Driving precision medicine through strategic marketing, real-world impact, and customer-focused execution.

San Diego, CA
Joined March 2013
Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)Photo by Richard Shippy (@RichShippy)
Richard Shippy retweeted
More to explore at #AMP2026. Join us for an Innovation Spotlight exploring methylation-aware WGS, advanced informatics, and biomarker discovery, plus Meet the Experts at booth 727. Learn More: bit.ly/4sgyPCM
3
5
1,241
Richard Shippy retweeted
#ASHG26 has come to a close, and what an incredible week of scientific discovery, collaboration, and innovation across our growing insight ecosystem. 🧬 From the power of AI to accelerate genomic insights to advances in multiomics and connected tools, our mission is clear: make it easier for researchers to move from complex data to meaningful discoveries. Swipe through a few of the highlights from an unforgettable week in Montréal. 👉 In case you missed it, register to see our on-demand sessions: bit.ly/3Wx5FDB
2
1
1
5
1,405
Richard Shippy retweeted
📸 When 'omics align, biology becomes clearer. 🧬 At #ASHG26, our Industry Education session explored how multiomics reveals new insight into human disease research. We heard from Illumina's Cande Rogert, St. Jude Children's Research Hospital's Jasmine Plummer, and Henry Ford Health's David Lanfear on the deep impact of connecting multiple layers of biological data. Multiomic research is helping them unlock new breakthroughs, from pinpointing changes in breast cancer tissue, to uncovering molecular signatures of heart disease, and identifying ancestry-based differences in prostate cancer gene expression. Swipe through highlights from the session! ➡️ And learn more about how we're advancing innovation at this year's ASHG Annual Meeting. illumina.com/events/conferen…
1
1
6
1,752
Richard Shippy retweeted
From connection to clarity. 🧬 #ASHG26 is here, and this week we're showcasing even more innovations for the insight ecosystem. From scientific sessions to an evening with leaders on the frontier of discovery, we're kicking off an exciting week of celebrations. And yes, we've painted Montréal Illumina orange! 🧡 Visit us at Booth #701 and keep an eye on our socials. There's plenty more to come! 👀 illumina.com/events/conferen…
1
1
5
1,650
Richard Shippy retweeted
We’re bringing genomic and multiomic innovation together at #ASHG26 in Montréal. Swipe and join us to see how the Illumina Insight Ecosystem helps turn complex data into insights that advance discovery: 🧬 Explore Illumina’s portfolio: Visit Illumina booth #701 to learn about our products, solutions, and partnership opportunities. 🔬 Hear from research leaders: Explore long-range genomic and epigenetic insights, multiomic approaches, and the role of data and software in biological discovery during our Industry Education sessions. 💡See innovation in action: Join our proteomics and array CoLab sessions to explore emerging research approaches and new perspectives on disease biology. 👀 Stay tuned: Keep an eye on our channels for announcements and updates from ASHG 2026! 🔗 Explore our full schedule: illumina.com/events/conferen…
1
4
5
1,707
Richard Shippy retweeted
She started at the bench, worked her way up, and helped break through the biggest bottleneck in genomics: cost. Now Cande Rogert is on a quest to simplify and democratize multiomics — and unlock Illumina’s next revolution 👇 Listen in as Global Head of R&D Cande Rogert and VP of Global Marketing Rich Shippy explore: 🔶 How bringing sequencing costs down revealed the next bottleneck—and why Illumina is now pushing to democratize multiomics 🔶 The “why” behind Cande’s journey to Illumina—her drive to understand disease, her role in shaping genomics and why she “bleeds Illumina orange” 🔶 Inside the customer conversations shaping Illumina’s multiomics portfolio—connecting assays, sequencing and analysis to help researchers uncover deeper biological insights 🔶 A sneak peek at what’s next for Illumina’s multiomics portfolio—and the ambition to bring more powerful science to labs of every size 🔗 Now live on our News Center, YouTube, and Spotify: illumina.com/company/news-ce…
1
7
13
3,166
Richard Shippy retweeted
🔬 Every hour spent troubleshooting is an hour not spent on discovery. That's why researchers like Klaus Wagner at @MedUniGraz value TruPath™ Genome for its streamlined workflows and high-quality data that help move research forward. Learn more: illumina.com/techniques/sequ… #Genomics #ScientificDiscovery
1
7
2,479
Richard Shippy retweeted
“We are on the brink of a revolution,” says Tomasz K. Wojdacz. Researchers at @pumszczecin in Szczecin Poland are using the @illumina 5-base solution to develop more accurate, standardized approaches to tumor classification. By bringing methylation and genomic sequencing data together, they’re gaining a powerful new lens into disease biology—and accelerating precision medicine.  Read more 👇 illumina.com/company/news-ce…
6
1
17
3,310
Richard Shippy retweeted
The first winners of the Illumina 5-Base for Cancer Research Grant Contest have been announced — recognized for scientific merit and their potential to advance cancer research through integrated genomic and epigenomic insights. Following a large number of high-quality and competitive applications from researchers around the world, our advisory committee of Illumina scientists and Medical Affairs representatives selected three outstanding grant recipients. Congratulations to: 🏆 Alfonso Bellacosa, MD, PhD, Professor, Nuclear Dynamics and Cancer Program, Cancer Epigenetics Institute, Fox Chase Cancer Center (USA) 🏆 Jacob Blum, MD/PhD Candidate in the Cellular and Molecular Medicine Graduate Program at Johns Hopkins School of Medicine (USA) 🏆 Richard Tothill, PhD, Associate Professor, The Collaborative Centre for Genomic Cancer Medicine - a joint venture between The University of Melbourne and Peter MacCallum Cancer Centre (Australia) We look forward to supporting their work with the Illumina 5‑base solution. Learn more about the Illumina 5‑Base for Cancer Research Grant Contest and this year’s recipients: illumina.com/techniques/sequ… #CancerResearch #Genomics #Epigenetics #Multiomics #PrecisionMedicine #NGS
2
7
2,180
Richard Shippy retweeted
Like our new wheels? 🚐 The @Illumina Bioinformatics Mobile Workstation is bringing DRAGEN™-powered high-performance computing directly to scientific and clinical research customers across mainland China. Designed to support localized analysis, it's another way we're helping researchers move from sequencing data to insight faster. Learn more: illumina.com/company/news-ce… #genomics #multiomics
1
3
1
5
2,215
Richard Shippy retweeted
Biology unfolds at the protein level. The study of proteins — or proteomics — captures the real-time activity of proteins that drive health and disease. As part of an integrated multiomic approach, understanding proteomics helps connect genetic variation to functional biological outcomes. Recent innovations are transforming proteomics from a targeted, low-throughput discipline into a scalable, high-throughput science that can be integrated with sequencing workflows. Today, Illumina is unveiling the latest updates to our SOMAmer™ proteomics technologies, which are designed to measure biologically meaningful proteomic signals at scale using synthetic affinity reagents — engineered for specificity. Now supported by more than 1,500 peer-reviewed publications demonstrating real-world biological relevance, our SOMAmer technologies offer unparalleled scale and reproducibility.
1
6
2
15
2,874
Richard Shippy retweeted
At #ESHG2026, we're showcasing how our sequencing and multiomics solutions are helping researchers unlock deeper biological insights. From discovery to impact, we’re advancing genomics to improve understanding of human health and disease. Visit Booth 328, June 13–15, and join our corporate sessions exploring the path from insight to impact: emea.illumina.com/events/con…
1
7
1,518
Richard Shippy retweeted
🎥At #EACR2026, integrated multiomics is transforming cancer research. With the launch of StrataMap Spatial, we’re expanding what’s possible with discovery at single‑cell resolution. Join the conversation at Booth 80 in Budapest to see how genomic, proteomic, and spatial data come together to unlock deeper insight. Plus, stop by our AI Photo Booth to join the league of genomics superheroes. Don’t miss our @illumina symposium tomorrow for a closer look at how these approaches are shaping the future of cancer research: emea.illumina.com/events/con…
3
8
1,532
Richard Shippy retweeted
Introducing StrataMap Spatial, a powerful end-to-end whole-transcriptome solution with unmatched breadth of coverage and resolution StrataMap Spatial expands researchers’ ability to understand the structure and function of tissues, study tumor microenvironments, and identify novel drug targets for precision medicine. (1/2) #EACR2026
1
9
1
17
3,471
Richard Shippy retweeted
What, exactly, is multiomics?" You might be asking how will it impact the future of research and medicine. To answer that, today we are introducing our Multiomics Explained series🧬 This will help elucidate the hottest topic in the industry since “genomics,” enabling you to understand how researchers are enhancing their studies with our innovative solutions that enable an entire ecosystem of insights. Explore the first installment 🔗 : illumina.com/company/news-ce…
3
16
2,207
Richard Shippy retweeted
“The most exciting time in the space of oncology.” At #ASCO26 we shared more about our recently announced whole-genome based molecular residual disease (MRD) research ecosystem –– changing the game for detection of cancer recurrence. As a distributed solution for MRD research, this technology will enable tumor fingerprinting and ctDNA tracking faster. Learn more: illumina.com/company/news-ce… #genomics #multiomics
1
1
5
1,695
Richard Shippy retweeted
Watch our first demo of the recently launched fireflyGO automation solution with the MiSeq i100 at #ASCO26 — an on-demand application library and on-board thermocycler means end-to-end library prep for Pillar oncoReveal panels has never been easier. 📍See fireflyGO in action at Booth #33106 and learn more on this announcement here: illumina.com/company/news-ce… @SPTLabtech @ASCO #genomics #multiomics
6
1
16
2,857
Richard Shippy retweeted
Illumina and @SPTLabtech are launching the new fireflyGO automation system—a benchtop solution designed to simplify and accelerate targeted oncology workflows. By integrating automated library preparation and liquid handling with the MiSeq i100 Series, fireflyGO helps laboratories: ✅ Reduce hands-on time and manual touchpoints ✅ Improve reproducibility and reliability ✅ Streamline workflows and scale operations ✅ Increase access to genomic testing in oncology The system also supports a growing menu of Pillar Biosciences oncoReveal panels, expanding flexibility for researchers working across solid tumors, hematologic malignancies, and lymphoid conditions. Together, these innovations reflect our ongoing commitment to making next-generation sequencing more accessible, efficient, and impactful—helping accelerate the adoption of genomics in cancer research and care. 📍See fireflyGO in action at the ASCO Annual Meeting (Booth #33106) in Chicago, May 29–June 2, and learn more on this announcement here: illumina.com/company/news-ce… #ASCO26
3
3
1,282
Richard Shippy retweeted
Molecular residual disease research is changing the game for detection of cancer recurrence. Now, @illumina is developing a new solution that will bring these genomic breakthroughs to more labs around the world. As a distributed whole-genome sequencing solution for MRD research — this technology will enable tumor fingerprinting and ctDNA tracking faster and for more patients. By combining whole-genome breadth with high analytical sensitivity and the power of DRAGEN, it’s designed to detect true tumor signal with precision. Learn more: illumina.com/company/news-ce… #ASCO26
1
3
10
1,613
Richard Shippy retweeted
At #ASCO26, we’re showcasing how genomic solutions are ushering in a new era of precision oncology. Join us at booth 33106 to see how Illumina is accelerating progress across the cancer continuum. Discover more: illumina.com/events/conferen…
2
1
8
934